Press Releases April 27, 2026 09:00 AM

Iperionx Webinar

IperionX schedules a webinar to update shareholders and investors on company developments

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
IPX

IperionX Limited announced a webinar hosted by Founder and CEO Taso Arima to provide a company update to shareholders and investors. The webinar will take place on April 28, 2026, at 9:00 am AEST / April 27, 2026, at 7:00 pm U.S. EDT.

Iperionx Webinar
IPX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • IperionX will hold a webinar featuring insights from the Founder and CEO, Taso Arima.
  • The event aims to update shareholders and investors on recent company developments.
  • The webinar is accessible via Zoom and requires prior registration.

SOUTH BOSTON, Va., April 27, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (Nasdaq | ASX: IPX) is pleased to invite shareholders and investors to a webinar on Tuesday April 28, 2026 at 9:00 am Australian Eastern Standard Time / Monday April 27, 2026 at 19:00 pm U.S. Eastern Daylight Time, where Founder and CEO, Taso Arima will provide a company update.

Details of the event are as follows:

Event:IperionX WebinarPresenter:Founder and CEO, Taso ArimaTime:Tue April 28, 2026 at 9:00 am AEST / Mon April 27, 2026 at 19:00 pm U.S. EDTWhere:Zoom webinarRegistration link:https://us06web.zoom.us/webinar/register/WN_C6hLA6i7T0uNyDW0u2RmwQ


After registering your interest, you will receive a confirmation email with information about joining the webinar.

Contacts

Anastasios (Taso) Arima, Founder and CEO
Toby Symonds, President
Dominic Allen, Chief Commercial Officer

Investors: investorrelations@iperionx.com
Media: media@iperionx.com

+1 980 237 8900
www.iperionx.com


Risks

  • Lack of specific financial or operational information in the update could leave investors uncertain about company prospects.
  • Market reaction might be muted if the webinar does not contain significant news or strategic announcements.
  • Potential risks include operational or market challenges inherent to the materials or mining sector served by the company.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026